The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

Table 4 Cox regression analysis of only adjuvant immunotherapy combinations

Variable		N (%)	Univariable analysis		Multivariable analysis
Variable		N (%)	Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
Immunotherapy	Adjuvant immunotherapy	106 (0.96)	0.98 (0.76–1.28)	0.907	1.00 (0.76–1.32)	0.995
Immunotherapy	No immunotherapy	10,950 (99.04)	Ref		Ref
CTx or CTxRTx plus immunotherapy	Adjuvant CTx or CTxRTx plus imm	90 (0.88)	0.97 (0.73–1.30)	0.854	1.01 (0.75–1.37)	0.935
CTx or CTxRTx plus immunotherapy	Adjuvant CTx or CTxRTx	10,104 (99.12)	Ref		Ref

We combined adjuvant chemotherapy plus immunotherapy with adjuvant chemoradiation plus immunotherapy due to small sample size. When analyzed separately the results were the same. CTx: chemotherapy, CTxRTx: chemoradiation therapy, imm: immunotherapy

ISSN: 1471-2407